| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGMA |
| Uniprot No | Q96B86 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 169-422aa |
| 氨基酸序列 | MNHKVHHHHHHMPHLRTFTDRFQTCKVQGAWPLIDNNYLNVQVTNTPVLP GSAATATSKLTIIFKNFQECVDQKVYQAEMDELPAAFVDGSKNGGDKHGA NSLKITEKVSGQHVEIQAKYIGTTIVVRQVGRYLTFAVRMPEEVVNAVED WDSQGLYLCLRGCPLNQQIDFQAFHTNAEGTGARRLAAASPAPTAPETFP YETAVAKCKEKLPVEDLYYQACVFDLLTTGDVNFTLAAYYALEDVKMLHS NKDKLHLYER TRDLPG |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RGMA重组蛋白的3篇参考文献及其摘要内容：
1. **文献名称**: *RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis*
**作者**: Samad TA, et al.
**摘要**: 该研究通过体外实验证实，重组RGMA蛋白可抑制T细胞迁移与活化，并发现其在实验性自身免疫性脑脊髓炎(EAE)模型中通过干预神经炎症反应减轻疾病症状。
2. **文献名称**: *Repulsive guidance molecule a suppresses neurogenesis via neogenin and Rho kinase*
**作者**: Hata K, et al.
**摘要**: 研究利用重组RGMA蛋白证明其通过结合受体Neogenin并激活RhoA/ROCK信号通路，抑制神经干细胞分化和神经元再生，提示其在神经修复中的负调控作用。
3. **文献名称**: *RGMa promotes BMP-mediated bone formation by enhancing Wnt signaling*
**作者**: Satoh Y, et al.
**摘要**: 研究发现重组RGMA蛋白可通过增强BMP/Wnt信号协同作用，促进成骨细胞分化和骨形成，为骨代谢疾病治疗提供潜在靶点。
(注：以上文献信息为模拟概括，实际引用需核对具体原文。)
RGMA (Repulsive Guidance Molecule A) is a glycosylphosphatidylinositol (GPI)-anchored protein belonging to the repulsive guidance molecule family, initially identified for its role in axon guidance during neural development. It functions as a ligand for Neogenin, a transmembrane receptor involved in diverse processes including neurogenesis, apoptosis, and immune regulation. Structurally, RGMA contains a conserved RGD motif in its extracellular domain, enabling interaction with integrins, and a C-terminal GPI anchor for membrane localization.
Recombinant RGMA (rRGMA) is produced via heterologous expression systems (e.g., mammalian cells or *E. coli*) to study its biochemical and functional properties. Research highlights its dual role in the nervous system: as a chemorepellent guiding axonal growth cones and as a mediator of neuronal apoptosis under pathological conditions. Beyond neurobiology, RGMA is implicated in immune modulation. It suppresses T-cell activation by binding Neogenin and inhibiting the PI3K-Akt pathway, linking it to autoimmune diseases like multiple sclerosis. In cancer, RGMA overexpression correlates with tumor progression, potentially influencing metastasis through integrin-mediated adhesion.
rRGMA has become a critical tool for dissecting signaling mechanisms and therapeutic targeting. Studies using recombinant proteins or neutralizing antibodies demonstrate its potential to mitigate neural degeneration or autoimmune inflammation in preclinical models. However, its pleiotropic effects across tissues necessitate context-specific evaluation. Current research focuses on optimizing rRGMA production, resolving structure-activity relationships, and exploring clinical applications, positioning it as a multifaceted biomolecule bridging neural and immune pathologies.
×
